Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!

Brianna "Chickenfry" LaPaglia, in a March 10 TikTok video, got candid about the growing use of GLP-1 weight loss medication.

Hindalco, L&T, Tata Steel, UltraTech Cement, JSW Steel were among biggest losers on the Nifty, while gainers included Tata Consumer, HUL, Bharti Airtel. All other sectoral indices ended in the red ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

With close to one million downloads, Shotsy is the most popular GLP-1 tracking app on the market, and now meets patients at every stage of their GLP-1 journey.

The Nifty ended below the 23,200 mark. All the sectoral indices on the NSE ended in the red with metal, PSU bank and auto indices declining the most.

An Informational Consumer Analysis of AgelessRx's Prescription Process, NAD+ Therapies, GLP-1 and Compounded Semaglutide Options, Off-Label Longevity Medications, and Cash-Pay Pricing Structure for 20 ...

Medications known as GLP-1 receptor agonists have become some of the most popular treatments for weight loss in recent years. These drugs, originally developed to help people with diabetes control ...

Biocon said its arm, Biocon Pharma, has received approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Liraglutide injection (gVictoza), 18 mg ...

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...

When fresh data appeared in the British Medical Journal in early 2026, it confirmed a suspicion that physicians had long ...